These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20014880)

  • 41. Is there a role for bevacizumab in the treatment of glioblastoma?
    Chi AS; Chamberlain MC
    Oncologist; 2013; 18(10):1080-2. PubMed ID: 24056893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab.
    Yoon YH; Kim JG; Chung H; Lee SY
    Acta Ophthalmol; 2009 Sep; 87(6):685-7. PubMed ID: 18705680
    [No Abstract]   [Full Text] [Related]  

  • 43. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
    Krämer I; Lipp HP
    Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Translating biological insights into clinical endpoints in neuro-oncology.
    Bredel M
    Lancet Oncol; 2009 Oct; 10(10):928-9. PubMed ID: 19628430
    [No Abstract]   [Full Text] [Related]  

  • 45. Hand eruption after intravenous administration of bevacizumab.
    Ruiz V; Garcia-Muret MP; Alomar A
    J Eur Acad Dermatol Venereol; 2011 Feb; 25(2):238-9. PubMed ID: 20477919
    [No Abstract]   [Full Text] [Related]  

  • 46. Herpetic epithelial keratitis after intravitreal injection of bevacizumab.
    Sakarya Y; Sakarya R; Yildirim A
    Cornea; 2010 Jul; 29(7):840; author reply 840. PubMed ID: 20574238
    [No Abstract]   [Full Text] [Related]  

  • 47. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC
    Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of bevacizumab in haemodialysis.
    Garnier-Viougeat N; Rixe O; Paintaud G; Ternant D; Degenne D; Mouawad R; Deray G; Izzedine H
    Nephrol Dial Transplant; 2007 Mar; 22(3):975. PubMed ID: 17093010
    [No Abstract]   [Full Text] [Related]  

  • 49. First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?
    Marosi C
    CNS Oncol; 2013 Nov; 2(6):473-4. PubMed ID: 25054815
    [No Abstract]   [Full Text] [Related]  

  • 50. Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome.
    Wick A; Schäfer N; Dörner N; Schemmer D; Platten M; Bendszus M; Wick W
    J Neurooncol; 2010 Mar; 97(1):157-8. PubMed ID: 19727565
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?
    Franceschi E; Brandes AA
    Expert Rev Anticancer Ther; 2011 May; 11(5):657-60. PubMed ID: 21554036
    [No Abstract]   [Full Text] [Related]  

  • 52. Bevacizumab therapy for glioblastoma: a passionate discussion.
    Desjardins A; Friedman HS
    CNS Oncol; 2014 Jan; 3(1):1-3. PubMed ID: 25054891
    [No Abstract]   [Full Text] [Related]  

  • 53. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.
    Stupp R; Weller M
    Neuro Oncol; 2014 Jun; 16(6):765-7. PubMed ID: 24826844
    [No Abstract]   [Full Text] [Related]  

  • 54. Bevacizumab for newly diagnosed glioblastoma.
    Gilbert MR; Sulman EP; Mehta MP
    N Engl J Med; 2014 May; 370(21):2048-9. PubMed ID: 24849088
    [No Abstract]   [Full Text] [Related]  

  • 55. Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1.
    Ullrich NJ; Zimmerman M; Smith E; Irons M; Marcus K; Kieran MW
    J Child Neurol; 2011 Feb; 26(2):228-30. PubMed ID: 20823033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rare serious complications of erlotinib therapy.
    Kapoor S
    Acta Neurochir (Wien); 2013 Apr; 155(4):743. PubMed ID: 23361636
    [No Abstract]   [Full Text] [Related]  

  • 57. Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?
    Fathpour P; Obad N; Espedal H; Stieber D; Keunen O; Sakariassen PØ; Niclou SP; Bjerkvig R
    Neuro Oncol; 2014 May; 16(5):754-6. PubMed ID: 24733853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response to: "rare serious complications of erlotinib therapy".
    D'Alessandris QG; Pallini R
    Acta Neurochir (Wien); 2013 Apr; 155(4):745. PubMed ID: 23275073
    [No Abstract]   [Full Text] [Related]  

  • 59. Sigmoid Colon Perforation Related to Bevacizumab in a Patient With Glioblastoma.
    Ozturk MA; Erdik B; Eren OO
    Am J Ther; 2016; 23(1):e241-2. PubMed ID: 23782762
    [No Abstract]   [Full Text] [Related]  

  • 60. [Superselective intra-arterial administration of bevacizumab with blood-brain barrier disruption in patients with recurrent malignant gliomas: case report and literature review].
    Kaprin AD; Zaitsev AM; Rerberg AG; Fedenko AA; Datsenko PV; Kirsanova ON
    Zh Vopr Neirokhir Im N N Burdenko; 2021; 85(5):64-70. PubMed ID: 34714005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.